Metformin in Non Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Metformin
Related studies linked through entity extraction aliases.
Platelet Rich Fibrin With 1% Metformin Gel for Treatment of Intrabony Defects
- Status
- COMPLETED
- Phase
- PHASE2
Trial With Metformin in Women With Polycystic Ovary Syndrome
- Status
- COMPLETED
- Phase
- PHASE4
A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
- Status
- UNKNOWN
- Phase
- PHASE2
Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus
- Status
- UNKNOWN
- Phase
- PHASE3
Use of Metformin in Treatment of Childhood Obesity
- Status
- COMPLETED
- Phase
- PHASE4
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
- Status
- TERMINATED
- Phase
- PHASE2
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
- Status
- COMPLETED
- Phase
- PHASE1
Metformin in Kidney Disease
- Status
- COMPLETED
- Phase
- PHASE2
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Dapagliflozin Effects on Epicardial Fat
- Status
- COMPLETED
- Phase
- PHASE4
Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
- Status
- COMPLETED
- Phase
- NA
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
- Status
- COMPLETED
- Phase
- PHASE1
Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Status
- COMPLETED
- Phase
- PHASE2
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
- Status
- COMPLETED
- Phase
- PHASE2